Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats Pius MaliakalMaen AbdelrahimRiyaz Basha PRECLINICAL STUDIES 04 January 2011 Pages: 853 - 861
Caspase-independent apoptosis induction of quorum-sensing autoinducer analogs against chronic myeloid leukemia K562 Masaharu HazawaMichiko KudoIkuo Kashiwakura PRECLINICAL STUDIES 05 January 2011 Pages: 862 - 869
Antimetastatic activity and low systemic toxicity of tetradecyl gallate in a preclinical melanoma mouse model Claudriana LocatelliDeborah Regina CarvalhoTânia Beatriz Creczynski-Pasa PRECLINICAL STUDIES 08 January 2011 Pages: 870 - 879
A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines Jessica CastroMarc RibóAntoni Benito PRECLINICAL STUDIES 01 February 2011 Pages: 880 - 888
In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83 Xiangrui LiuFrankie LamShudong Wang PRECLINICAL STUDIES 18 February 2011 Pages: 889 - 897
Inhibition of TGF-β signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol Annegret SerweKristina RudolphGerhard Erkel PRECLINICAL STUDIES 22 February 2011 Pages: 898 - 915
Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice Grace-Ifeyinwa OnimoeAiguo LiuJiayuh Lin PRECLINICAL STUDIES 22 February 2011 Pages: 916 - 926
Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model Uwe PohlenHeinz J. BuhrChristoph Holmer PRECLINICAL STUDIES 01 March 2011 Pages: 927 - 935
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model Timothy P. BurkholderJoshua R. ClaytonJames J. Starling PRECLINICAL STUDIES 01 March 2011 Pages: 936 - 949
DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057 John A. HartleyAnzu HamaguchiPhilip W. Howard PRECLINICAL STUDIES 08 March 2011 Pages: 950 - 958
Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens Danilo D. RochaAruna BalgiClaudia Pessoa PRECLINICAL STUDIES 18 March 2011 Pages: 959 - 966
Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2 Alicia A. GoyenecheErin E. SeidelCarlos M. Telleria PRECLINICAL STUDIES Open access 22 March 2011 Pages: 967 - 980
In vivo toxicity study of N-1-sulfonylcytosine derivatives and their mechanisms of action in cervical carcinoma cell line Jelena Kašnar-ŠamprecIvana RatkajBiserka Žinić PRECLINICAL STUDIES 22 March 2011 Pages: 981 - 990
Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes Berta OtováIwao OjimaIvan Gut PRECLINICAL STUDIES 30 March 2011 Pages: 991 - 1002
Aminopyrimidoisoquinolinequinone (APIQ) redox cycling is potentiated by ascorbate and induces oxidative stress leading to necrotic-like cancer cell death David R. VásquezJulien VerraxPedro Buc Calderon PRECLINICAL STUDIES 05 April 2011 Pages: 1003 - 1011
A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen Dennis MaPhillip TremblaySiyaram Pandey PRECLINICAL STUDIES 15 April 2011 Pages: 1012 - 1027
Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways Gili Berkovitch-LuriaMichal WeitmanZvi Malik PRECLINICAL STUDIES 21 April 2011 Pages: 1028 - 1038
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design Amye TevaarwerkGeorge WildingGlenn Liu PHASE I STUDIES 12 January 2011 Pages: 1039 - 1045
Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma Masashi NiwakawaKatsuyoshi HashineYoshiteru Sumiyoshi PHASE I STUDIES 19 January 2011 Pages: 1046 - 1054
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients Yutaka FujiwaraNaomi KiyotaHironobu Minami PHASE I STUDIES Open access 08 February 2011 Pages: 1055 - 1064
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel Michael MillwardPaul MainwaringMatthew A. Spear PHASE I STUDIES 16 February 2011 Pages: 1065 - 1073
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma Steven J. O’DayAnna C. PavlickBrenda Foster PHASE I STUDIES 18 February 2011 Pages: 1074 - 1081
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer Elwyn C. CabebeGeorge A. FisherBranimir I. Sikic PHASE I STUDIES 15 March 2011 Pages: 1082 - 1087
A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors Kyle HolenRobert DiPaolaMark Stein PHASE I STUDIES 22 March 2011 Pages: 1088 - 1095
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors Akira FukutomiKiyohiko HatakeNobuyuki Yamamoto PHASE I STUDIES 12 April 2011 Pages: 1096 - 1106
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia H. M. KantarjianS. PadmanabhanM. Minden PHASE I STUDIES 15 April 2011 Pages: 1107 - 1115
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials Antonin LevyLaurence Albiges-SauvinJean-Charles Soria PHASE I STUDIES 21 April 2011 Pages: 1116 - 1120
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia Simona LapusanMaria B. VidrialesJean-Pierre Marie PHASE I STUDIES 26 April 2011 Pages: 1121 - 1131
Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non–small cell lung cancer Isamu OkamotoNobuyuki YamamotoKazuhiko Nakagawa PHASE I STUDIES 03 May 2011 Pages: 1132 - 1137
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer Dirk StrumbergBeate SchultheisK. Mross PHASE II STUDIES 21 December 2010 Pages: 1138 - 1143
A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer Xin ZhaoKai MeiQiu Li PHASE II STUDIES 12 January 2011 Pages: 1144 - 1149
Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study Soohyeon LeeSang Hyun YoonHye Jin Choi PHASE II STUDIES 20 January 2011 Pages: 1150 - 1157
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium Helen J. MackayHeather J. AuAmit M. Oza PHASE II STUDIES 12 March 2011 Pages: 1158 - 1163
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research Do-Youn OhKeun Wook LeeYung-Jue Bang PHASE II STUDIES 15 March 2011 Pages: 1164 - 1174
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer A. B. El-KhoueiryR. K. RamanathanH. J. Lenz PHASE II STUDIES 22 March 2011 Pages: 1175 - 1183
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group) Beate SchultheisDirk StrumbergMax E. Scheulen PHASE II STUDIES 12 April 2011 Pages: 1184 - 1192
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials Axel Le CesneAlejandro YovineGeorge D. Demetri PHASE II STUDIES 12 April 2011 Pages: 1193 - 1202
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer Daniel J. RenoufPatricia A. TangMalcolm J. Moore PHASE II STUDIES 28 April 2011 Pages: 1203 - 1207
The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan Marije SlingerlandHans Gelderblom PHASE II STUDIES Open access 06 May 2011 Pages: 1208 - 1210
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium Manish R. SharmaKristen WroblewskiHedy L. Kindler PHASE II STUDIES 07 May 2011 Pages: 1211 - 1215
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy György BodokyConstanta TimchevaN. C. Tebbutt PHASE II STUDIES 19 May 2011 Pages: 1216 - 1223
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials Kohei ShitaraJunko IkedaKeitaro Matsuo PHASE III STUDIES 25 February 2011 Pages: 1224 - 1231
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia Craig ReynoldsNicholas Di BellaLina Asmar PHASE III STUDIES 16 September 2011 Pages: 1232 - 1240
Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy Youlia M. KirovaVincent ServoisPhilippe Beuzeboc SHORT REPORT 14 December 2010 Pages: 1241 - 1243
Everolimus-related organizing pneumonia: a report establishing causality Justine FrijaDominique JolyPierre-Régis Burgel SHORT REPORT 29 December 2010 Pages: 1244 - 1247
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells David DavidsonYannick CoulombeLawrence Panasci Short Report 11 January 2011 Pages: 1248 - 1256
TRAIL shows potential cardioprotective activity Barbara ToffoliStella BernardiPaola Secchiero SHORT REPORT 04 January 2011 Pages: 1257 - 1260
Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor Edgardo S. SantosJorge E. GomezLuis E. Raez REVIEW 25 February 2011 Pages: 1261 - 1269
Erratum to: Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model Timothy P. BurkholderJoshua R. ClaytonJames J. Starling Erratum 20 May 2011 Pages: 1270 - 1271
Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy György BodokyConstanta TimchevaN. C. Tebbutt Erratum 26 July 2011 Pages: 1272 - 1273